Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 18/20 | 0.46 |
| ▸ | HTR2A | P28223 | 7/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792362 | 0.80 | FES (0.42) | CCR3ROCK2 | |
| SCHEMBL6794493 | 0.79 | CDK2 (0.36) | ROCK2 | |
| SCHEMBL6793287 | 0.77 | ROCK2 (0.36) | ROCK2 | |
| SCHEMBL6799797 | 0.77 | AAK1 (0.35) | — | |
| Hydrochloric Acid SCHEMBL4263501 | 0.76 | CYP3A4 (0.34) | HTR2AROCK2SLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL6792947 | 0.76 | CYP1A2 (0.38) | — | |
| Trifluoroacetic Acid SCHEMBL6793644 | 0.75 | CDK2 (0.36) | HTR2AROCK2 | |
| SCHEMBL1659385 | 0.75 | CDK2 (0.34) | ROCK2 | |
| Trifluoroacetic Acid SCHEMBL6797949 | 0.74 | PTGES (0.39) | — | |
| Trifluoroacetic Acid SCHEMBL6790792 | 0.74 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CCR3 3934/4885HTR2A 1489/4885ROCK2 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.